



Resource impact statement

Resource impact

Published: 14 August 2019

www.nice.org.uk

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).

This is because dacomitinib is a further treatment option and the overall cost of treatment will be similar. Around 1,500 people may be eligible to receive dacomitinib.

Dacomitinib has a commercial arrangement (single discount patient access scheme). This makes dacomitinib available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme contact PfizerNICEaccount@pfizer.com.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.